Post-chemotherapy cognitive impairment

WikiDoc Resources for Post-chemotherapy cognitive impairment
Articles
Most recent articles on Post-chemotherapy cognitive impairment Most cited articles on Post-chemotherapy cognitive impairment Review articles on Post-chemotherapy cognitive impairment Articles on Post-chemotherapy cognitive impairment in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Post-chemotherapy cognitive impairment Images of Post-chemotherapy cognitive impairment Photos of Post-chemotherapy cognitive impairment Podcasts & MP3s on Post-chemotherapy cognitive impairment Videos on Post-chemotherapy cognitive impairment
Evidence Based Medicine
Cochrane Collaboration on Post-chemotherapy cognitive impairment Bandolier on Post-chemotherapy cognitive impairment TRIP on Post-chemotherapy cognitive impairment
Clinical Trials
Ongoing Trials on Post-chemotherapy cognitive impairment at Clinical Trials.gov Trial results on Post-chemotherapy cognitive impairment Clinical Trials on Post-chemotherapy cognitive impairment at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Post-chemotherapy cognitive impairment NICE Guidance on Post-chemotherapy cognitive impairment NHS PRODIGY Guidance FDA on Post-chemotherapy cognitive impairment CDC on Post-chemotherapy cognitive impairment
Books
Books on Post-chemotherapy cognitive impairment
News
Post-chemotherapy cognitive impairment in the news Be alerted to news on Post-chemotherapy cognitive impairment News trends on Post-chemotherapy cognitive impairment
Commentary
Blogs on Post-chemotherapy cognitive impairment
Definitions
Definitions of Post-chemotherapy cognitive impairment
Patient Resources / Community
Patient resources on Post-chemotherapy cognitive impairment Discussion groups on Post-chemotherapy cognitive impairment Patient Handouts on Post-chemotherapy cognitive impairment Directions to Hospitals Treating Post-chemotherapy cognitive impairment Risk calculators and risk factors for Post-chemotherapy cognitive impairment
Healthcare Provider Resources
Symptoms of Post-chemotherapy cognitive impairment Causes & Risk Factors for Post-chemotherapy cognitive impairment Diagnostic studies for Post-chemotherapy cognitive impairment Treatment of Post-chemotherapy cognitive impairment
Continuing Medical Education (CME)
CME Programs on Post-chemotherapy cognitive impairment
International
Post-chemotherapy cognitive impairment en Espanol Post-chemotherapy cognitive impairment en Francais
Business
Post-chemotherapy cognitive impairment in the Marketplace Patents on Post-chemotherapy cognitive impairment
Experimental / Informatics
List of terms related to Post-chemotherapy cognitive impairment

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D., Maria Fernanda Villarreal, M.D. [2]

Synonyms and keywords: Chemotherapy-induced cognitive dysfunction; Chemo brain; Chemo fog; Chemobrain; PCCI

Overview

Post-chemotherapy cognitive impairment (also known as chemotherapy-induced cognitive dysfunction) is defined as the cognitive impairment that can result from chemotherapy treatment. Post-chemotherapy cognitive impairment was first discovered and described in 1980. Post-chemotherapy cognitive impairment is characterized by changes in memory, fluency, and other cognitive abilities that impeded their ability to function as they had pre-chemotherapy. Approximately 20-30% of patients that undergo chemotherapy experience some level of post-chemotherapy cognitive impairment. The exact pathogenesis of post-chemotherapy cognitive impairment is not fully understood. However, the underlying mechanisms of the disease are believed to be caused by direct neurotoxicity. Genes involved the development of post-chemotherapy cognitive impairment, include: COMT nucleotide polymorphism, Apolipoprotein E gene, and BDNF gene mutations. Post-chemotherapy cognitive impairment is more commonly observed among middle aged and elderly patients. The median age at diagnosis ranges between 40-70 years old. There are no specific imaging findings associated with post-chemotherapy cognitive impairment. However, in some cases MRI may detect accurate measurement of therapy-induced changes in gray and white matter volumes. Recent studies suggest further investigation on the underlying mechanisms of cognitive impairment.

Historical Perspective

Post-chemotherapy cognitive impairment was first discovered and described in 1980 following the increasing number of breast cancer survivors.

Classification

There is no classification system for post-chemotherapy cognitive impairment.

Pathophysiology

• The pathogenesis of post-chemotherapy cognitive impairment is not fully understood.
• However, the underlying pathophysiology is believed to be caused by direct neurotoxicity.
• Genes involved the development of post-chemotherapy cognitive impairment, include:

• COMT nucleotide polymorphism
• Apolipoprotein E
• BDNF gene

Causes

• Common causes of post-chemotherapy cognitive impairment, include:

• Cyclophosphamide
• 5-fluorouracil
• Methotrexate

Differentiating Post-Chemotherapy Cognitive Impairment from Other Diseases

• Post-chemotherapy cognitive impairment must be differentiated from other diseases that cause cognitive impairment (such as, lack of attention, orientation to time and space), such as:

• Dehydration
• Infection
• Sepsis

Epidemiology and Demographics

• Post-chemotherapy cognitive impairment is rare.
• Approximately 20-30% of patients that undergo chemotherapy experience some level of post-chemotherapy cognitive impairment.
• The prevalence of post-chemotherapy cognitive impairment remains unknown.

Age

• Post-chemotherapy cognitive impairment is more commonly observed among patients aged 40-70 years old.
• Post-chemotherapy cognitive impairment is more commonly observed among middle aged adults and elderly patients.

Gender

• Females are slightly more commonly affected with post-chemotherapy cognitive impairment than males.

Race

• There is no racial predilection for post-chemotherapy cognitive impairment.

Risk Factors

The most common risk factor in the development of post-chemotherapy cognitive impairment include:

• are number of cycles of chemotherapy.
• Smoking

Screening[edit | edit source]

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Natural History, Complications and Prognosis

• The majority of patients with post-chemotherapy cognitive impairment are initially symptomatic.
• Early clinical features, include:

• Lack of attention
• Memory loss
• Problems to recall
• Lack of orientation

• If left untreated, patients with post-chemotherapy cognitive impairment may progress to develop severe cognitive impairment.
• Common complications of post-chemotherapy cognitive impairment, include:

• Decreased executive function
• Cerebrovascular disorders
• Focal neurological deficits

• Prognosis will generally good, and symptoms of post-chemotherapy cognitive impairment typically disappear in about four years.

Diagnosis

History and Symptoms

• Post-chemotherapy cognitive impairment is usually symptomatic at diagnosis
• Symptoms of post-chemotherapy cognitive impairment may include the following:

• Memory loss
• Lack of attention
• Difficult language fluency
• Poor calculation and recall
• Loss of appetite
• Irritability or constant mood swings
• Hopelessness

• A directed history should be obtained to ascertain:

• Aggravating factors, such as:

• Anxiety
• Depression

Physical Examination

• Patients with post-chemotherapy cognitive impairment usually appear malnourished and pale.
• Physical examination shows no remarkable findings for patients with post-chemotherapy cognitive impairment.

Laboratory Findings

• There are no specific laboratory findings associated with post-chemotherapy cognitive impairment.
• In some cases, elevated levels of apolipoprotein (APOE) allele may be seen in patients with post-chemotherapy cognitive impairment

Electrocardiogram[edit | edit source]

There are no ECG findings associated with [disease name].

OR

An ECG may be helpful in the diagnosis of [disease name]. Findings on an ECG suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

X-ray[edit | edit source]

There are no x-ray findings associated with [disease name].

OR

An x-ray may be helpful in the diagnosis of [disease name]. Findings on an x-ray suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no x-ray findings associated with [disease name]. However, an x-ray may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Echocardiography or Ultrasound[edit | edit source]

There are no echocardiography/ultrasound findings associated with [disease name].

OR

Echocardiography/ultrasound may be helpful in the diagnosis of [disease name]. Findings on an echocardiography/ultrasound suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no echocardiography/ultrasound findings associated with [disease name]. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

CT scan[edit | edit source]

There are no CT scan findings associated with [disease name].

OR

[Location] CT scan may be helpful in the diagnosis of [disease name]. Findings on CT scan suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no CT scan findings associated with [disease name]. However, a CT scan may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

MRI[edit | edit source]

There are no MRI findings associated with [disease name].

OR

[Location] MRI may be helpful in the diagnosis of [disease name]. Findings on MRI suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no MRI findings associated with [disease name]. However, a MRI may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Other Imaging Findings[edit | edit source]

There are no other imaging findings associated with [disease name].

OR

[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies[edit | edit source]

There are no other diagnostic studies associated with [disease name].

OR

[Diagnostic study] may be helpful in the diagnosis of [disease name]. Findings suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

Other diagnostic studies for [disease name] include [diagnostic study 1], which demonstrates [finding 1], [finding 2], and [finding 3], and [diagnostic study 2], which demonstrates [finding 1], [finding 2], and [finding 3]

Treatment

Medical Therapy

• There is no treatment for post-chemotherapy cognitive impairment; the mainstay of therapy is supportive care.
• Common medical therapies for the treatment of post-chemotherapy cognitive impairment, include:

• Hormonal therapy

Surgery

• Surgery is not recommended for patients with post-chemotherapy cognitive impairment.

Primary Prevention

• There are no primary preventive measures available for post-chemotherapy cognitive impairment.
• Once diagnosed and successfully treated, patients with post-chemotherapy cognitive impairment are followed-up every visit.
• Follow-up testing includes cognitive function assessments (such as, mini–mental state examination)